Navigation Links
Two-Year Follow-Up Data Show Outstanding Clinical Outcomes and Safety for OrbusNeich's Genous™ Stent in Patients at High Risk for Restenosis
Date:8/16/2011

HONG KONG, Aug. 16, 2011 /PRNewswire/ -- OrbusNeich today announced that the that the company's Genous Stent showed no significant difference in the rate of target vessel failure (TVF) at two years compared to the Taxus Liberte™ paclitaxel-eluting stent in patients with de novo coronary artery lesions carrying a high risk for restenosis.  The two-year follow-up data from the prospective, randomized TRIAS pilot study were published in Catheterization and Cardiovascular Interventions.

No cases of stent thrombosis (ST) were observed in patients treated with the Genous Stent at two years, compared to five cases of ST observed in four patients treated with Taxus. The cumulative rate of cardiac death or myocardial infarction (MI) was 4.1 percent in the Genous group compared to 6.3 percent in the Taxus group.

"It is noteworthy that we did not see any stent thrombosis in patients with complex lesions treated with the Genous Stent," said Marcel Beijk, M.D., of the Academic Medical Center, Amsterdam, and lead author of the paper. "We also saw that the Genous Stent tended to have fewer episodes of target lesion revascularization between one and two years."

The single-center study investigated 193 patients of which 98 received a Genous Stent and 95 received a Taxus stent. Dual antiplatelet therapy was prescribed for at least one month after Genous Stent implantation and for at least six months after Taxus stent implantation.

"For patients with a high risk of restenosis who cannot tolerate the long-term dual antiplatelet therapy normally associated with DES, it is clear that the Genous Stent is an excellent alternative," added Prof. Robbert de Winter, M.D., Ph.D., also of the Academic Medical Center, Amsterdam, and an author of the paper.

The study's primary endpoint was TVF and secondary endpoints included non-cardiac death, target lesion revascul
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
2. Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) EXPRESS(R) Stents and Bypass Surgery
3. Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
4. Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
5. Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
6. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
7. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
8. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
9. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... quarter and six months ended June 30, 2015. ... ITP are progressing and we continue to expect results ... , president and chief executive officer of Rigel. "We ... clinical programs, including evaluating fostamatinib for new treatment indications, ...
(Date:8/4/2015)... 2015  Dr. Keesha Ewers of ... approval of flibanserin, or what is being touted ... of decreased female sexual desire back several decades. ... and addressing libido as a singular symptom with ... Photo - ...
(Date:8/4/2015)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at ... in New York . A live webcast ... A replay will be available approximately one hour after the ...
Breaking Medicine Technology:Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2
... FORT MYERS, Fla., May 11, 2011 Radiation ... radiation therapy centers, today announced financial results for the first ... the first quarter of 2011 were $156.5 million, an increase ... same quarter of 2010. The increase in revenue was principally ...
... 2011 Doctors in Germany are among the first ... with the REVIVE™ SE, a new self-expanding blood clot ... and restore blood flow to the brain in patients ... Inc., a global neuroscience and neurovascular company, received Conformite ...
Cached Medicine Technology:Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 2Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 3Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 4Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 5Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 6Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 7Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 8Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 9Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 10Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 11Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 2Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 3
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power ... Products is expanding its reach in Texas. Effective July 1st of this year, ... Texas generator division. With the North Texas acquisition, Worldwide Power Products (“WPP”) ...
(Date:8/4/2015)... ... 04, 2015 , ... Recent studies in the ... in binge drinking among certain populations and specific locations. Researchers, who ... examine trends and evidence to help facilitate health care treatment to meet current ...
(Date:8/4/2015)... NJ (PRWEB) , ... August 04, 2015 , ... Members ... on quality care metrics – at a cost that is nine percent lower -- ... Blue Cross Blue Shield of New Jersey’s patient-centered programs. , “The promise of ...
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... ... August 04, 2015 , ... NutraScience Labs , a ... services, joined over 200 other Long Island-based corporations as participants in the 10th ... at Jones Beach State Park in Wantagh, New York. , According to Mindy ...
Breaking Medicine News(10 mins):Health News:North Texas Acquisition Press Release 2Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2
... , NEW YORK, Dec. 11 Often called "the ... Miracle,s for their significant contribution to today,s beauty industry ... Award in the mass skin care market category. ... My Goodbye Acne System , the first ...
... The National Medical Association (NMA) applauds the announcement ... Tom Daschle as the Secretary of Health and Human ... of Health and Human Services. , We ... to provide a comprehensive national health care reform benefiting ...
... WASHINGTON, Dec. 11 Speaker Nancy Pelosi released the following ... Leader Tom Daschle as Secretary of Health and Human Services ... Office of Health Reform: , , ... Services and his selection as Director of the new White ...
... Dec. 11 The American Academy of Orthopaedic Surgeons ... guideline on "Treatment of Osteoarthritis of the Knee". These ... less invasive than knee replacement surgery. While a wide ... tailored to individual patients after discussions with their physicians. ...
... Clinic researchers have discovered that a chemical known as ... the effectiveness of tamoxifen in treating breast cancer, and ... way. , Their study, being presented at the Cancer ... 31st annual San Antonio Breast Cancer Symposium, finds that, ...
... MINNEAPOLIS/ST. PAUL (Dec. 11, 2008) The University of Minnesota has received ... Family Foundation. Goals for the funding, to be paid over five ... to accelerate the timeline to translate it into a viable cure for ... The gift is the ...
Cached Medicine News:Health News:DR. MIRACLE'S Wins 2008 WWD Beauty Biz Award: Breakthrough Product of the Year!!! 2Health News:National Medical Association Applauds Choice of Health and Human Services Secretary 2Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 2Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 3Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 2Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 3Health News:University of Minnesota receives $40 million for type 1 diabetes research 2Health News:University of Minnesota receives $40 million for type 1 diabetes research 3Health News:University of Minnesota receives $40 million for type 1 diabetes research 4
... Designed To Safely And Easily ... Smaller Incision.,Specially Designed To Cut And ... With Ease With One Instrument.,New Miniaturized ... Phaco Incision For Explantation Of A ...
... 8-12108 : Designed To Be Used ... Length Radials Placed On The Cornea For Making ... Be Used With The Gills Nomograms. 6mm & ... For Making Limbal Relaxing Incisions.5mm Inner Circle Assists ...
... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture., ,Open And Close ... Access To The Globe During Clear ...
... Jaw Design Holds The Lens Securely ... Polished Blades Keep The Optic From ... Control Over Release Of The Optic.,Wide ... Tilting During Insertion.,Reusable, Autoclaveable, Made In ...
Medicine Products: